• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Optalgin® Drops new
    / Abic


    Active Ingredient
    Dipyrone 500mg / ml (20 drops)

    Status in Israel
    OTC

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Bottle

    50 ml

    not in the basket chart

    Dosage

    Adults and adolescents over 15 years old (weighing over 53 kg): 20-40 drops, up to 3 times a day.
    Children:
    3-11 months (5-8 kg) 2-4 drops, up to 3 times a day.
    1 – 3 years (9 – 15kg) 3 – 10 drops, up to 3 times a day.
    4 – 6 years (16 – 23kg) 5 – 15 drops, up to 3 times a day.
    7 – 9 years (24 – 30 kg) 8 – 20 drops, up to 3 times a day.
    10 – 12 years (31 – 45 kg) 10 – 30 drops, up to 3 times a day.
    13 – 14 years (46 – 53 kg) 15 – 35 drops, up to 3 times a day.
    The medicine should be taken at 6-8 hour intervals. Not more than three doses in 24 hours.
    Please refer to the license holder for further details.


    Indications

    Relief of moderate to severe pain, such as headache, toothache, and menstrual pain, and for reducing high fever that does not respond to other treatment measures.


    Contra-Indications

    Hypersensitivity to dipyrone (metamizole) or  other pyrazolones (such as propyphenazone, phenazone) or pyrazolidines (such as phenylbutazone, oxyphenbutazone); this also includes patients who have, for example, developed a significant reduction in certain white blood cells (agranulocytosis) after using these active ingredients.
    Patients with  known sensitivity to analgesics (asthma syndrome induced by taking pain analgesics, or sensitivity to analgesics experienced as urticaria/angioedema).
    Patients with bone marrow impairment.
    Patients with   hematopoietic system disorders.
    Patients with acute intermittent hepatic porphyria.
    Please refer to the license holder for further details.


    Special Precautions

    Please refer to the license holder for further details.


    Side Effects

    Please refer to the license holder for further details.


    Drug interactions

    Please refer to the license holder for further details.


    Pregnancy and Lactation

    Pregnancy: To be used during pregnancy after a thorough benefit-risk  assessment.
    May be used after week 28 in the lowest dosage effective no more than 3 g (120 drops) /day and not for more than 3-4 days.
    Lactation
    : Only if not responding to other treatments as the breakdown products may pass through the milk.


    Overdose

    Please refer to the license holder for further details.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    CLOSE